Background
Marine metabolites
bistramides A-D and K have all displayed certain degrees of bioactivity. In particular, bistramide K has been reported
to exhibit lower cytotoxicity in vivo as well as inhibit human non-small pulmonary carcinoma
(NSCLC-N6) in the G1 phase of the cell.